News

NICE approves trastuzumab emtansine after deal with drug company

BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j2930 (Published 16 June 2017) Cite this as: BMJ 2017;357:j2930
  1. Zosia Kmietowicz
  1. The BMJ

A new deal on the advanced breast cancer drug trastuzumab emtansine (marketed by Roche as Kadcyla) means that it can now be recommended for routine use on the NHS, the National Institute for Health and Care Excellence (NICE) has said.1

The latest draft guidance on trastuzumab emtansine reverses a previous recommendation issued last December in which NICE said that the drug was too expensive.2 The cost of £90 000 (€103 000; $115 000) for an average course of treatment (14.5 months) gives trastuzumab a cost per quality adjusted life year (QALY) of £166 000, which was well above the normal threshold for drugs used …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe